Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Onyx Pharmaceuticals, Inc. (NQ: ONXX)
88.80 USD  -1.18 (-1.31%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 90.23
Bid (Size) 88.73 (400)
Ask (Size) 88.80 (500)
Prev. Close 89.98
Today's Range 87.16 - 90.36
52wk Range 43.73 - 101.57
Shares Outstanding 72,738,263
Dividend Yield N/A
Top News
More News
Critical Alerts For Anheuser-Busch InBev, GlaxoSmithKline, Capital One, Safeway, and Onyx Pharmaceuticals Released By InvestorsObserver
June 14, 2013
from PR Newswire
Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
June 14, 2013
Editor Note: For more information about this release, please scroll to bottom. Read More
from PR Newswire

More News
Read More
Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)
June 12, 2013
category Regeneron Pharmaceuticals , amgen , Benzinga , and 35 more.
from Latest Articles from Benzinga.com
VB, RKT, ONXX, BEAV: ETF Inflow Alert
June 12, 2013
category ETFs
from ETF Channel
Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
June 06, 2013
from Marketwired News Releases
It’s Hard to Win the Pharma News Game
June 04, 2013
category Market Outlook , NYSE:SNY , NASDAQ:ONXX , and 1 more.
from InvestorPlace - Latest Headlines
Onyx Pharmaceuticals Bearish Moving Average Crossover Alert (ONXX)
June 03, 2013
from Comtex SmarTrend® News Briefs
Onyx Pharmaceuticals and the UCSF Helen Diller Family Comprehensive Cancer Center Announce Oncology Innovation Alliance
June 03, 2013
from Marketwired News Releases
Onyx Phase 3 Nexavar DECISION Trial Shows Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer
June 02, 2013
category ONXX , Benzinga , Events , and 1 more.
from Latest Articles from Benzinga.com
Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thy
June 02, 2013
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here